Hana Serajeddini

Hana Serajeddini

Auto-generated profile, based on publicly available information

Hana Serajeddini

Division of Respirology, Department of Medicine, Western University, London, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2023 in Chest
Verified
Journal Article
Open access
MMMarrissa J. McIntosh
Marrissa J. McIntosh
HKHarkiran K. Kooner
Harkiran K. Kooner
RERachel L. Eddy
Rachel L. Eddy
AWAngela Wilson
Angela Wilson
HSHana Serajeddini
Hana Serajeddini
GPGrace Parraga
Grace Parraga
We previously showed in patients with poorly controlled eosinophilic asthma that a single dose of benralizumab resulted in significantly improved Asthma Control Questionnaire (ACQ-6) score and 129Xe MRI ventilation defect percent (VDP) 28 days postinjection, and 129Xe MRI VDP and CT airway mucus occlusions were shown to independently predict this early ACQ-6 response to benralizumab. Do early VDP responses at 28 days persist, and do FEV1, fractional exhaled nitric oxide, and mucus plug score improve during a 2.5 year treatment period? Participants with poorly controlled eosinophilic asthma completed spirometry, ACQ-6, and MRI, 28 days, 1 year, and 2.5 years after initiation of treatment with benralizumab; chest CT was acquired at enrollment and 2.5 years later. Of 29 participants evaluated at 28 days post-benralizumab, 16 participants returned for follow-up while on therapy at 1 year, and 13 participants were evaluable while on therapy at 2.5 years post-benralizumab initiation. As compared with 28 days post-benralizumab, ACQ-6 score (2.0 ± 1.4) significantly improved after 1 year (0.5 ± 0.6, P = .02; 95% CI, 0.1-1.1) and 2.5 years (0.5 ± 0.5, P = .03; 95% CI, 0.1-1.1). The mean VDP change at 2.5 years (-4% ± 3%) was greater than the minimal clinically important difference, but not significantly different from VDP measured 28 days post-benralizumab. Mucus score (3 ± 4) was significantly improved at 2.5 years (1 ± 1, P = .03; 95% CI, 0.3-5.5). In six of eight participants with previous occlusions, mucus plugs vanished or substantially diminished 2.5 years later. VDP (P < .001) and mucus score (P < .001) measured at baseline, but not fractional exhaled nitric oxide or FEV1, independently predicted ACQ-6 score after 2.5 years. In poorly controlled eosinophilic asthma, early MRI VDP responses at 28 days post-benralizumab persisted 2.5 years later, alongside significantly improved mucus scores and asthma control.

3 April 2025 in ERJ Open Research
Verified
Journal Article
Open access
AMAli Mozaffaripour
Ali Mozaffaripour
STSam Tcherner
Sam Tcherner
EDEveline Durom
Eveline Durom
HKHarkiran K Kooner
Harkiran K Kooner
MMMarrissa J McIntosh
Marrissa J McIntosh
GPGrace Parraga
Grace Parraga
Background: In asthma, fluticasone-furoate/umeclidinium/vilanterol (FF/UMEC/VI) was previously demonstrated to improve FEV1and asthma-control, but the mechanism by which this occurs, especially at the level of the small-airways, is not well-understood. We asked the question, does FF/UMEC/VI influence asthma-control by improving airway structure-function and airway occlusions? Hence, here our objective was to measure airway structure-function using129Xe MRI ventilation-defect-percent (VDP), CT and airwave-oscillometry after 6-weeks single-inhaler FF/UMEC/VI and 1-year later.Methods: Participants with GINA4-5 asthma who were poorly controlled on inhaled-corticosteroid/long-acting-bronchodilator (ICS/LABA), provided written-informed-consent to baseline, 6-, and 12-week visits as well as an open-extension 1-year visit. All received FF/UMEC/VI (200/62.5/25 µg) at baseline and underwent MRI, spirometry, plethysmography and oscillometry, pre- and post-bronchodilator (BD). Asthma-control (ACQ-6), asthma-quality-of-life (AQLQ) and St. George's Respiratory-Questionnaire (SGRQ) were completed. CT was acquired at baseline and 1-year later.Results: Thirty-one participants (24 females, 54±15 yrs) completed baseline, 28 (21 females, 54±15 yrs) completed the 6-week and 15 patients attended the 1-year visit. At 6-weeks, there was significantly improved pre-BD VDP (p=.02), FEV1(p=.008), distal-airways-resistance (R5–19; p=.001), AQLQ (p<.001) and SGRQ-scores (p=.001), which persisted at 1-year. VDP improved in participants with elevated mucus-score and eosinophil-count, while R5–19improvements were independent of type-2 inflammation. Mean airway mucus-score, lumen-area and total-airway-count were significantly improved at 1-year.Conclusions: In participants with GINA4-5 asthma, who had been poorly controlled on ICS/LABA, single-inhaler FF/UMEC/VI resulted in improved VDP and FEV1at 6-weeks. These improvements persisted 1-year later when airway markers were also significantly improved, consistent with the reversal of airway remodeling.

20 May 2025 in Chest
Verified
Journal Article
Open access
HSHana Serajeddini
Hana Serajeddini
ATAshutosh Thakar
Ashutosh Thakar
MKMelanie Kjarsgaard
Melanie Kjarsgaard
CHChynna Huang
Chynna Huang
NRNandhitha Ragunayakam
Nandhitha Ragunayakam
SSSarah Svenningsen
Sarah Svenningsen
Airway inflammation is a hallmark feature of asthma characterized by elevated eosinophils and/or neutrophils. Eosinophils in sputum can contribute to ventilation defects. The functional consequence of other types of cellularity on ventilation is unknown. What is the effect of different sputum cellular phenotypes on abnormal ventilation evaluated by 129Xe magnetic resonance imaging (MRI) in patients with severe asthma? Eighty-five patients with severe asthma and 15 healthy controls underwent 129Xe ventilation MRI. Sputum cytometry was performed to evaluate airway inflammation and stratify patients with asthma into four cellular phenotypes (paucigranulocytic, eosinophilic, neutrophilic, and mixed-granulocytic). Abnormal ventilation, quantified as the post-bronchodilator MRI ventilation defect percent (VDP), was compared between asthma sputum cellular phenotypes and to healthy controls. Demographics, clinical characteristics, and sputum cytokine levels of paucigranulocytic asthmatics with MRI VDP above and below the upper limit of normal were also compared. Ventilation was abnormal (MRI VDP above the upper limit of normal) for 44% (14 of 32) of asthmatics with paucigranulocytic sputum, 64% (14 of 22) of those with eosinophilic bronchitis, 75% (9 of 12) with neutrophilic bronchitis, and 89% (17 of 19) with mixed-granulocytic bronchitis. Compared to healthy controls, MRI VDP was higher in asthma participants with a eosinophilic (adjusted p=0.0002), neutrophilic (adjusted p=0.0001), and mixed-granulocytic phenotype (adjusted p<0.0001) but not paucigranulocytic (adjusted p=0.051). Among paucigranulocytic asthmatics, those with an MRI VDP above the upper limit of normal were older (p=0.006), had higher fractional exhaled nitric oxide (p=0.02), and higher computed tomography mucus scores (p<0.0001). In severe asthma, ventilation is abnormal in the presence of intraluminal cellular inflammation, irrespective of phenotype. Abnormal ventilation in paucigranulocytic asthma may be due to airway mucus and is often associated with elevated fractional exhaled nitric oxide.

28 May 2024 in Chest
Verified
Journal Article
Open access
HKHarkiran K. Kooner
Harkiran K. Kooner
HSHana Serajeddini
Hana Serajeddini
RERachel L. Eddy
Rachel L. Eddy
CYCory Yamashita
Cory Yamashita
SSSarah Svenningsen
Sarah Svenningsen
GPGrace Parraga
Grace Parraga